glp-1 obesity drug news today sep 30 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Alarming rise in weight loss

Description

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation

doi: 10.1097/TP.0000000000005496.

Heres how to deal.

Gastroparesis, also known as stomach paralysis, is not typically life-threatening, but complications from the condition can be fatal.

The combination therapy of GLP-1 receptor agonists and metformin demonstrates superior safety over monotherapy, while revealing novel adverse events and demographic-specific risk patterns, thereby offering reliable evidence to inform clinical practice.